Next Article in Journal
A New Era of Integration between Multiomics and Spatio-Temporal Analysis for the Translation of EMT towards Clinical Applications in Cancer
Previous Article in Journal
Human Embryonic Stem Cell-Derived Immature Midbrain Dopaminergic Neurons Transplanted in Parkinsonian Monkeys
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cells
Volume 12
Issue 23
10.3390/cells12232739
cells-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Research Progress in Transforming Growth Factor-β2

by
Meng-Yan Wang
1,†,
Wen-Juan Liu
1,†,
Le-Yi Wu
1,
Gang Wang
1,*,
Cheng-Lin Zhang
1,2,* and
Jie Liu
1
1
Department of Pathophysiology, Shenzhen University Medical School, Shenzhen 518060, China
2
Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen 518000, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Cells 2023, 12(23), 2739; https://doi.org/10.3390/cells12232739
Submission received: 25 October 2023 / Revised: 19 November 2023 / Accepted: 28 November 2023 / Published: 30 November 2023
(This article belongs to the Section Cell Signaling)
Browse Figures
Review Reports Versions Notes

Abstract

:
Transforming growth factor-beta 2 (TGF-β2), an important member of the TGF-β family, is a secreted protein that is involved in many biological processes, such as cell growth, proliferation, migration, and differentiation. TGF-β2 had been thought to be functionally identical to TGF-β1; however, an increasing number of recent studies uncovered the distinctive features of TGF-β2 in terms of its expression, activation, and biological functions. Mice deficient in TGF-β2 showed remarkable developmental abnormalities in multiple organs, especially the cardiovascular system. Dysregulation of TGF-β2 signalling was associated with tumorigenesis, eye diseases, cardiovascular diseases, immune disorders, as well as motor system diseases. Here, we provide a comprehensive review of the research progress in TGF-β2 to support further research on TGF-β2.

1. Introduction

The transforming growth factor-β (TGF-β) family is a superfamily of growth factors that play critical roles in regulating growth, development, immunity, inflammation, and tissue repair. To date, 33 members of the TGF-β superfamily have been identified in the human genome, including TGF-βs, bone morphogenetic proteins, growth differentiation factors, etc. [1]. The TGF-βs include three members, namely, TGF-β1, -β2, and -β3. Among them, the TGF-β1 homodimer is considered the prototype as it was the first TGF-β family protein to be biochemically characterised and readily available as a purified protein for experimental use [2,3]. The TGF-β signalling cascade is initiated by the binding of mature ligands to corresponsive receptors on the cell surface, forming a complex that activates Smad or non-Smad molecules to transduce signals into the nucleus and regulate the expression of target genes [4]. Due to their high similarity in protein sequence and structure, TGF-β1, -β2, and -β3 share similar receptors and intracellular signalling molecules. Most researchers tend to assume that the biological functions of TGF-β2 and TGF-β3 are equivalent to those of TGF-β1. However, a growing body of evidence has shown that TGF-β2 has many specificities that are different from those of TGF-β1 and TGF-β3. For example, TGF-β1 and TGF-β3 both have high binding affinities with the type 2 receptor (TβR2), whereas the affinity of TGF-β2 to TβR2 is much lower [5]. Further evidence from TGF-β1, TGF-β2, and TGF-β3 global knockout mice suggests that their physiological functions are significantly different (Table 1). About 60% of Tgfb1−/− mice die at the embryonic stage. Some postnatal Tgfb1−/− mice showed no obvious developmental abnormalities but eventually died around 20 days after birth due to a multifocal mixed inflammatory cell response, and organ failure [6]. Tgfb3−/− mice die within 20 h of birth with delayed lung development and defective palatogenesis [7]. In comparison, Tgfb2−/− mice exhibit more pronounced perinatal mortality and multiple developmental abnormalities that affect the cardiac, pulmonary, craniofacial, skeletal, palate, eye, inner ear, and urogenital organs [8]. The number of articles published each year on the topic of TGF-β2 has been increasing since 1987 when TGF-β2 was first described by Ikeda and colleagues (Figure 1A). Visualisation of the frequency of research keywords shows that the hot topics for TGF-β2 are its expression, activation, and roles in inflammation, tumorigenesis, differentiation, apoptosis, and extracellular matrix production in vivo and in vitro (Figure 1B). However, there is currently no available summary of the research progress on TGF-β2. Therefore, this review aims to provide an overview of recent advances in the expression, activation, regulation, and biological function of TGF-β2.

2. The Molecular Biology of TGF-β2

2.1. The Expression and Procession of TGF-β2

The amino acid sequence of TGF-β2 is highly conserved among species (Figure 2A). The human TGFB2 gene is located on chromatin 1q41 and contains seven or eight exons. There are two isoforms of human TGFB2 mRNA. Isoform 1 mRNA has a total length of 5952 bp and encodes a protein of 442 amino acids, while isoform 2 mRNA has a total length of 5868 bp and encodes a protein of 414 amino acids [10]. Isoform 1 has an additional 87 bp coding sequence that encodes 29 amino acids (tvcpvvttpsgsvgslcsrqsqvlcgyld) (https://www.ncbi.nlm.nih.gov/protein/NP_001129071.1, accessed on 1 October 2023). These amino acids replace an Asn (n) residue located at position 116 in the N-terminus of the TGF-β2 isoform 2 precursor protein (Figure 2B). Since the active form of TGF-β2 is located at the C-terminus, both isoforms express exactly the same mature TGF-β2. Similarly, mouse Tgfb2 mRNA also has two isoforms, with isoform 2 containing a 29-amino-acid insertion (tvcpvvttpsgslgsfcsrqsqvlcgyld) replacing the Asn (n) at the 116 position of isoform 1. Similar to humans, both isoforms express the same mature TGF-β2. The additional 29 amino acids of human isoform 1 and mouse isoform 2 contain three cysteine residues, which are essential for the stable protein conformation, dimerisation, and activation of TGF-β2. However, it is unclear whether differences in the N-terminus of the two isoforms affect the shear and release of mature TGF-β2.
Similar to other TGF-β isoforms, the pre-propeptide of TGF-β2 consists of three fragments, namely, the N-terminal signal peptide, the latent-associated peptide (LAP), and the C-terminal mature fragment [4]. After the pre-propeptide leaves for the endoplasmic reticulum from the ribosome, the N-terminal signal peptide is cleaved, and the remaining fragment (propeptide) enters the lumen. The conjugation sites of LAP and the mature peptide can be cleaved by furin protease and fold to form a homodimeric or heterodimeric complex called the small latent complex (SLC). The processing of the SLC is accompanied by the cross-linking of the N-terminal LAP to other secreted proteins, including the latent TGF-β binding proteins (LTBPs) and trans-membrane leucine-rich repeat protein glycoprotein-A repetitions predominant protein (GARP) [11]. GARP appears to be restricted to regulatory T cells and platelets, whereas LTBPs are ubiquitously expressed, which suggests that LTBPs may have broader impacts on TGF-β functions [12,13,14]. The LTBP family consists of four isoforms (LTBP-1, -2, -3, and -4), among which LTBP-1 and -3 can efficiently bind to all three members of TGF-β. By contrast, LTBP-4 has a weak binding affinity with TGF-β1, whereas LTBP-2 cannot interact with any isoforms of TGF-β [15,16]. SLC and LTBP form a protein known as the large latent complex (LLC). The LLC is delivered to the Golgi apparatus after assembly in the endoplasmic reticulum. Then, LLC is exocytosed into secretory vesicles, where it is released into the extracellular matrix (ECM) [17]. The deposition of latent TGF-β on the ECM is mediated by LTBP, which provides the scaffolding that binds latent TGF-β to ECM proteins such as fibrillins and fibronectins (Figure 3).

2.2. The Activation of TGF-β2

In the LLC, the LAP covers the key amino acids of the C-terminal dimer that are used to interact with its receptors, and this covering can cause the inactivation of the mature dimer ligand [17]. Therefore, TGF-β2 activation requires the dissociation or proteolysis of LLC in the ECM to release the dimeric TGF-β2 ligand. A common feature of these activators is that they all indicate perturbation of the ECM. Here, we discuss some established TGF-β2 activators (Table 2).
Integrin: The LAPs of TGF-β1 and -β3 contain the integrin-binding sequence RGD (Arg-Gly-Asp). Mice lacking the integrins αvβ6 and αvβ8 have phenotypic defects similar to those of TGF-β1 and -β3 knockout mice. However, TGF-β2 cannot be activated by integrin because TGF-β2 does not contain the RGD sequence in the LAP [18,19].
Proteases: Many proteases can activate TGF-β, including plasmin, serine protease, matrix metalloproteinase (MMP-2, MMP-9), plasma kallikrein, etc. [20,21,22,23]. These proteases activate LLC by directly digesting the LAP or indirectly digesting ECM components. Prostate-specific antigen (PSA) is a serine protease. It is generally considered to be a clinical marker of prostate cancer. In fact, PSA could play a role in the activation of latent TGF-β. In contrast to plasmin, which is known to activate both latent TGF-β1 and TGF-β2, PSA was found to activate only latent TGF-β2 in prostate epithelial cells [24].
Thrombospondin-1: Thrombospondin-1 (TSP-1) is a component of the ECM. Physiologically, TSP-1 is secreted by platelets, but a number of other cells are also capable of producing it, including smooth muscle cells, astrocytes, endothelial cells, and various tumour cells [25]. TSP-1 has a binding site for LAP and serves as an activator of TGF-β. In antigen-presenting cells and glioma cells, TSP-1 has been reported to efficiently activate TGF-β2 [26,27].
Reactive oxygen species: When latent TGF-β was exposed to Fe(III)/ascorbate-generated reactive oxygen species (ROS), only latent TGF-β1 showed significant activation, while latent TGF-β2 and latent TGF-β3 did not. This is because the direct target of ROS is methionine 253, a methionine unique to LAP-β1, where its side chain is oxidised, leading to conformational alterations that result in the activation of latent TGF-β1 [28].
pH: Treating NRK-49F and AKR-MCA cell-conditioned medium with extreme pH (1.5 or 12) resulted in significant activation of TGF-β1, whereas mild acidity (pH 4.5) resulted in only 20–30% of the effect achieved with pH 1.5, and little or no TGF-β1 activity was produced at a pH between 5.5 and 7.5 [29]. Another study showed that the sensitivity of recombinant human TGF-β1 and TGF-β2 to acids and bases is basically the same. Both isoforms were activated in the acidic (pH 3.1–4.1) and alkaline (pH 11.0–11.9) ranges. In contrast, recombinant chicken TGF-β3 was activated under acidic (pH 2.5–3.1) and alkaline (pH 10.0–12.3) conditions [30].
Heat: Thermal activation of latent TGF-β was measured with the growth inhibition of the mink lung cell line CCL-64. Complete activation of recombinant latent TGF-β1 was observed at 70 °C for 10 min, 75 °C for 5 min, and 85–90 °C for 1 min. The thermal stability of the different latent forms was compared at 25–100 °C for 5 min. Recombinant latent TGF-β1, TGF-β2, and TGF-β3 showed similar activation trends at 25–75 °C, but latent TGF-β2 and TGF-β3 showed a sustained increase in activation from 80 to 100 °C, whereas the activation of latent TGF-β1 decreased [30]. However, the impact of heat on TGF-βs activity has not been verified with in vivo experiments, and their physiological and pathological significance in the body needs to be further investigated.
Mechanical force: In an early report, researchers found that shear stress-induced an overall decrease in TGF-β pathway molecules, including TGF-β2, TGF-β3, TβR1, and TβR2 expression in tendon cells [31]. However, TGF-β1 was upregulated in response to stirring or shear force. Subsequently, TGF-β1 was also shown to be strongly activated when subjected to mechanical forces in vitro and in vivo. One possible molecular mechanism by which stirring and shear may influence the activation of latent TGF-β1 is thiol-disulphide exchange [32]. The reason for the difference in the mechanical force required to activate TGF-β1, TGF-β2, and TGF-β3 is still unclear. Whether this difference is caused by the difference in some amino acid sites of LAP requires further experimental evidence.
Table 2. Comparison of factors affecting the activation of three isoforms of TGF-β.
Table 2. Comparison of factors affecting the activation of three isoforms of TGF-β.
ActivatorsTGF-β1TGF-β2TGF-β3Reference
IntegrinsActivateUnable to activateActivate[18,19]
ProteasesActivateActivateActivate[24]
TSP-1ActivateActivateNA[26,27]
ROSActivateUnable to activateUnable to activate[28]
pH
pH 3.1–4.1
pH 11.0–11.9		ActivateActivateNA[30]
pH 2.5–3.1NANAActivate
pH 10.0–12.3
Heat
70 °C (10 min)Fully activateNANA[30]
75 °C (5 min)Fully activatePartially activatePartially activate
85–90 °C (1 min)Fully activateNANA
100 °C (5 min)Partially inactiveFully activateFully activate
Mechanical forceActivateNANA[31,32]
NA, not available.

2.3. The Signalling Pathway of TGF-β2

Receptors

There are three types of TGF-βs receptors, namely, TβR1, TβR2, and TβR3 (betaglycan). TβR1 and TβR2 were found to have serine/threonine and tyrosine kinase activity, while TβR3 showed no kinase activity. TGF-β1-3 has different affinities for the three receptors, so the way they activate downstream signalling pathways is also different [33]. TGF-β1 and TGF-β3 have strong affinity with TβR2. When TβR1 and TβR2 coexist, TGF-β1 and TGF-β3 first bind to TβR2, induce the autophosphorylation of TβR2, and then recruit TβR1 to form a tetrameric complex. Phosphorylation of the glycine–serine enrichment domain (GS-domain) of TβR1 leads to the activation of the downstream signalling pathway. Compared with TGF-β1 and TGF-β3, the affinity of TGF-β2 for TβR2 is much lower [5]. The reason for the different affinity between TGF-β1-3 and the receptors may be that TGF-β1 and TGF-β3 contain Arg25, Val92, and Arg94, while these three amino acids in TGF-β2 are replaced by Lys25, Ile92, and Lys94 [34]. TβR3 is a necessary co-receptor for TGF-β2 to perform some physiological regulatory functions, and its high affinity with TGF-β2 enhances the response of target cells to TGF-β2 [35,36]. After interacting with active TGF-β2, TβR3 can recruit and combine with TβR2, which can further recruit TβR1 to form a complex. Thereafter, TβR3 dissociates from the above complex and eventually forms the TGF-β2/TβR1/TβR2 complex to carry out the activation of the downstream signalling pathway [37]. In vivo studies have shown phenotypic similarities between Tgfb2−/− and Tgfbr3−/− mice, such as embryonic lethality and cardiac dysplasia [38,39]. In vitro studies have also shown that mouse embryonic fibroblasts with TβR3 knockdown are significantly less sensitive to the TGF-β2 response, while this effect is not observed for other TGF-β ligands [38]. These studies suggest that the cardiac developmental defects caused by TβR3 deletion mutations may be related to the weakened signalling of TGF-β2, which further indicates that TβR3 is an important co-receptor for TGF-β2 to play the regulatory function of cardiac development. However, it is important to note that TβR3 does not always have a positive effect on TGF-β2 signalling. TβR3 has a soluble form, which is the cleaved extracellular fragments of full-length TβR3. Researchers found that adding soluble TβR3 to mink lung epithelial cells strongly inhibited TGF-β2 signal transduction. The addition of 0.6 nM soluble TβR3 was able to reduce the binding of TGF-β2 to TβR1 and TβR2 by 90% and to reduce the growth inhibitory effect of 5 pM TGF-β2 by 50% [40]. Further experiments are needed to determine whether TβR3 can play a dual regulatory function in vivo and to prove its utility as a TGF-β2 modulator. In addition, not all TGF-β2 regulatory processes depend on TβR3. In the absence of TβR3, the TGF-β2 signal could also be partially transduced by TβR2-B in a Smad-dependent manner. TβR2-B is an alternatively spliced variant of TβR2 and is expressed in cells that are sensitive to TGF-β2 such as osteoblasts and mesenchymal precursor cells. Compared with TGF-β1, only minor responsiveness to TGF-β2 was observed in L6 skeletal muscle cells that did not express either TβR3 or TβR2-B. However, transfection of TβR3 or TβR2-B significantly increased the response of L6 cells to TGF-β2 (Figure 4) [41].

2.4. The Regulation of TGF-β2 Expression (Table 3)

2.4.1. Transcription Factors

Cyclic AMP-responsive element-binding protein H: Cyclic AMP responsive element binding protein H (CREBH) is a transcription factor that is enriched in the liver and is known to regulate the hepatic acute phase response and lipid homeostasis. Patients with hepatitis C had higher serum TGF-β2 than a healthy population, and the concentration of TGF-β2 was positively correlated with hepatic fibrosis stages. Meanwhile, the mRNA level of Tgfb2 was increased after hepatic stellate cells were infected with the hepatitis C virus. Silencing CREBH inhibits, while overexpressing CREBH upregulates, the transcription of TGF-β2. Using chromatin immunoprecipitation assays, one study further identified a CREBH binding element at −49 to −43 in the TGFB2 promoter region [42].
Oestrogen-related receptor: Oestrogen-related receptor γ (ERRγ) is a nuclear receptor that serves as a constitutive activator of transcription. In CCl4-induced acute liver injury models, TGF-β2 expression and secretion were increased in an ERRγ-dependent manner. Promoter assays further demonstrated that the promoter region of the human TGFB2 gene contains an ERRγ binding element at −1686 to −1676, which mediates the direct transcriptional regulation of TGFB2 by ERRγ [43].
Homeobox: Homeobox B7 (HoxB7) is a transcription factor that is critically involved in tumorigenesis. TGF-β2 expression was upregulated in four MMTV-HoxB7/Her2 transgenic mouse tumour cell lines and two breast cancer cell lines after HOXB7 overexpression, whereas TGF-β2 expression was reduced in HoxB7-depleted cells. Using luciferase and chromatin immunoprecipitation assays, one study further identified that HoxB7 can directly bind to the promoter region of TGF-β2 and activate its transcription [44]. HoxA10 is another member of the homeobox superfamily involved in tumour progression. TGF-β2 is a target gene of HoxA10. Overexpression of HoxA10 increases TGF-β2 transcription by interacting with tandem cis-elements in the promoter [45].
Snail: Snail is a pro-fibrotic transcription factor implicated in epithelial-to-mesenchymal transition (EMT) and tumour metastasis. In pancreatic cancer-susceptible mice (Kras mutation), pancreatic acinar cell-specific Snail overexpression upregulated the expression of TGF-β2 and enhanced pancreatic fibrosis, while the expression of TGF-β1 and TGF-β3 were not significantly changed. Similarly, the overexpression of Snail in AsPC1 and Panc1 cell lines selectively upregulates TGF-β2 with no effect on TGF-β1 or TGF-β3 [46].
Activating transcription factor: Activating transcription factor 3 (ATF3) is a member of the activating transcription factor/cAMP-responsive element-binding protein family of transcription factors. In HUVECs, ATF3 selectively binds to the promoter region of TGFB2, but not TGFB1, thereby activating TGF-β2 expression and facilitating endothelial to mesenchymal transformation [47]. In addition, the direct binding of phospho-ATF2 to the TGFB2 promoter region is one of the mechanisms by which all-trans-retinoic acid increases TGF-β2 expression in intestinal epithelial cells [48].
Peroxisome proliferator-activated receptors: Peroxisome proliferator-activated receptors (PPARs) are a group of transcription factors that play essential roles in cellular differentiation, development, and metabolism. The PPARγ agonist efatutazone negatively regulated the mRNA and protein expression of TGF-β2 in non-small cell lung cancer cell lines [49]. In contrast, fenofibrate, a potent PPARα agonist, significantly increased TGF-β2 secretion in mouse subcutaneous white adipose tissue cells and partially explained the mechanism for exercise-induced lactate regulation of TGF-β2 [50].
Regulatory factor X: Regulatory factor X (RFX) is another transcription factor that plays an inhibitory role in TGFB2 transcription. Researchers found that TGFB2 promoter activity was decreased in the neuroblastoma cell line overexpressing RFX. Their study further demonstrated that the inhibitory effect of RFX on TGFB2 transcription is mediated by its direct binding to the promoter region (−113 to −100) of the human TGFB2 gene (Table 3) [51].

2.4.2. Noncoding RNA

MicroRNAs: MicroRNAs (miRNAs) are a class of endogenous noncoding RNAs with ~22 nt that can bind with complementary sequences on mRNAs, resulting in mRNA degradation and/or translational inhibition [52]. TGF-β2 expression is regulated by a variety of miRNAs. For example, TGFB2 is a direct target of miR-7-5p with the RNA pull-down assay and the dual luciferase reporter gene assay. In an acidic tumour microenvironment, the expression of miR-7-5p was reduced, alleviating its suppressive effect on the TGFB2 mRNA 3′ untranslated region (3′UTR). As a result, the metastatic potential of lung cancer increased [53]. miR-148a downregulated the expression of TGFB2 in gastric cancer cells, which contributed to the inhibition of tumour cell proliferation and metastasis [54]. miR-193a-3p is another miRNA that can suppress TGFB2 expression by binding directly to the 3′UTR of TGFB2. miR-193a-3p expression was significantly reduced along with upregulated TGF-β2 levels in human heart tissue from congenital heart disease. miR-193a-3p mimics suppressed TGF-β2 expression in H9C2 cells, while miR-193a-3p inhibitor increased TGF-β2 expression [55]. miR-29b-3p and miR-29c-3p can target to the 3′UTR region of Tgfb2 in mouse cardiac fibroblasts [56]. Similarly, miR-200a binds to the 3′UTR of Tgfb2 and suppresses its expression in rat proximal tubular epithelial cells to prevent renal fibrosis [57]. miR-148b downregulates TGF-β2 to promote angiogenesis and inhibit endothelial-to-mesenchymal transition during skin wound healing [58]. Tgfb2 mRNA expression was significantly downregulated in miR-31 mimic-treated mouse keratinocyte cells. In “Hairpoor” mice, miR-31 downregulation was accompanied by significant upregulation of TGF-β2, which can cause abnormal hair cycle in hair loss mutant mice. In contrast, there was no change in Tgfb1 mRNA expression. In that study, the researchers further identified that the 3′ UTR at 4161~4181 bp of Tgfb2 is the direct target of miR-31 in keratinocytes [59]. In addition, Tgfb2 inhibition by miR-193b resulted in early chondrogenesis defection in chondrogenic ATDC5 cells [60]. miR-466a-3p targets Tgfb2 in mouse CD4+T cells to inhibit its effect in inducing regulatory T cell differentiation from naive CD4 cells [61].
Circular RNAs: Circular RNAs (circRNAs) are a type of noncoding RNAs that play crucial roles in various pathological processes. circUbe2k can promote TGF-β2 expression by sponge miR-149-5p in the development of hepatic fibrosis [62]. circ_0001293 can clear the upstream inhibitory regulator (miR-8114) of TGF-β2 and increase its expression level. This circ_0001293/miR-8114/TGF-β2 axis has an anti-inflammatory effect in astrocytes, which might be a potential therapeutic target for epilepsy [63]. In addition, circRIP2 can sponge miR-1305 to upregulate TGF-β2, thereby inducing EMT and promoting proliferation and metastasis of bladder cancer cells [64].
Long noncoding RNA: Similar to the regulatory mechanism of circRNAs, there is another noncoding RNA, named long noncoding RNA (lncRNA). Increased expression of lncRNA cancer susceptibility candidate 9 (lncRNA CASC9) is associated with tumorigenesis and cancer progression. lncRNA CASC9 could upregulate the expression of TGF-β2 by sponging miR-758-3p, thereby accelerating bladder cancer progression [65]. In addition, another recent study reported that lncMIAT promotes markers of liver fibrosis with the upregulation of TGF-β2 by competitive sponging of miR-16-5p [66]. From the studies above, it is not difficult to speculate that the inhibition of TGF-β2 expression from the perspective of miRNA could be a good strategy for the treatment of a variety of diseases.

2.4.3. External Stimulus

Glycoproteins: Glypican-3 (GPC3) is a cell surface glycoprotein that is highly expressed in hepatocellular carcinoma cells. According to Sun and co-workers, GPC3 silencing is correlated significantly with increased TGF-β2 expression, while having no significant effect on TGF-β1 and TGF-β3 expression. The antiproliferative effects of GPC3 silencing were partially attenuated by co-transfection of siRNA-GPC3 with siRNA-TGF-β2, indicating that TGF-β2 is a critical target of GPC3 in inducing cell proliferation [67]. Another study suggested that glycated collagen in the cardiac interstitium strongly increases the expression of TGF-β2, which is important for the formation of myofibroblasts and the fibrosis that occurs in diabetic cardiomyopathy [68]. However, the mechanism of the above two glycoproteins on TGF-β2 expression has not been clearly elucidated.
Lipoprotein: High-density lipoproteins (HDLs) are known as cholesterol carriers that have cardiovascular protective properties. Using cDNA array analysis, Norata et al. identified that TGF-β2, but not TGF-β1 or TGF-β3, is selectively increased by HDL in endothelial cells in a PI3K/Akt-dependent manner [69].
Cytokines: IL-4 and IL-13 stimulated the release of TGF-β2, but not TGF-β1 or TGF-β3, from human bronchial epithelial cells in a time- and concentration-dependent manner. IFN-γ was found to antagonise the stimulatory effects of IL-4 and IL-13 on TGF-β2 expression and secretion [70,71]. In addition, there was a trend towards a decrease in TGF-β2 mRNA in both Il1b−/− and Il1r1−/− mice, suggesting that IL-1β may have a positive role in TGF-β2 expression [72].
H2O2: There was a significant increase in TGF-β2 protein levels at the molecular weight of 12.5 kD after the treatment of human umbilical vein endothelial cells (HUVECs) with 10 μM H2O2 for 72 h. H2O2-induced phosphorylation of p38 MAPK might be a potential mechanism for the increase in TGF-β2 expression [73].
Hypoxia: Hypoxia (1%O2) can also increase the expression of TGF-β2 at both mRNA and protein levels in HUVECs. Mechanistically, Smad binding elements (CAGA box) at the −77 to −40 bp region of the TGFB2 promoter are activated under hypoxia, which can enhance its transcription [74].
Lactate: TGF-β2 expression is closely linked to lactate metabolism. Tumour cells highly express lactate dehydrogenase type A (LDH-A), a key metabolic enzyme that catalyses the conversion of pyruvate into lactate. Small interfering RNA against LDH-A (siLDH-A) concentration-dependently suppressed TGF-β2 expression in HTZ-349 glioma cells, whereas lactate induced it [75]. Another study further revealed that lactate promotes TGF-β2 expression by inducing TSP-1, a TGF-β2 activating protein. The authors further found that both TSP-1 and TGF-β2 levels were reduced in glioma cells treated with siLDH-A and that the inhibition of TSP-1 results in a reduction in TGF-β2. Conversely, reduced levels of TGF-β2 protein can be rescued with the addition of synthetic TSP-1 [27].
Mechanical forces: Several kinds of mechanical forces can also affect TGF-β2 expression, including cell density and shear stress. A study on the effect of cell density on TGF-β2 in murine corneal epithelial cells found that TGF-β2 was only detected in conditioned media from cells seeded at 50,000 cells/cm2, but not at 500 or 5000 cells/cm2 [76]. When comparing sheared and unsheared tendon cells, unidirectional shear stress can downregulate the expression of TGF-β2 using cDNA microarrays and Northern blot analyses [31]. However, the mechanism of these mechanical factors on TGF-β2 is not yet clear.
Table 3. The regulation of TGF-β2 expression.
Table 3. The regulation of TGF-β2 expression.
EffectMechanismDiseases or Cell TypesReference
External stimulus
Glypican 3DownregulateNAHepatocellular carcinoma[67]
Glycated- collagenUpregulateNADiabetic- cardiomyopathy[68]
HDLUpregulateActivate PI3K/AktAtherosclerosis[69]
TGF-β1DownregulateNAFibroblastic cell[77]
TGF-β2UpregulateInhibit Smad7Necrotising enterocolitis[78]
IL-4 IL-13UpregulateNAAsthma[70]
IFN-γDownregulateActivate JAK-STAT Retinal diseases[71]
IL-1βUpregulateNARenal fibrosis[72]
H2O2UpregulateActivate p38 MAPK Systemic inflammation[73]
HypoxiaUpregulateActivate CAGA boxEndothelial cell[74]
LactateUpregulateActivate by thrombospondin-1Glioma[27]
Cell densityUpregulateNACorneal epithelial [76]
Shear stressDownregulateNATendon cell[31]
Transcription factors
CREBHUpregulateBind promoter region at −49 to −43Hepatitis C[42]
ERRγUpregulateBind promoter region at −1686 to −1676Acute liver injury[43]
HOXB7UpregulateBinding region unknownBreast cancer[44]
HOXA10UpregulateBinding region unknownAcute myeloid leukemia[45]
SnailUpregulateBinding region unknownPancreatic cancer[46]
ATF3UpregulateBinding region unknownVascular diseases[47]
ATF2UpregulateBinding region unknownIntestinal epithelial cells[48]
PPARαUpregulateBinding region unknownGlycolipid metabolism[50]
PPARγDownregulateBinding region unknownNonsmall cell lung cancer[49]
RFXDownregulateBind promoter region at −113 to −100Neuroblastoma[51]
Noncoding RNA
miR-7-5pDownregulateBind 3′UTRLung cancer metastasis[53]
miR-148aDownregulateBind 3′UTRGastric cancer[54]
miR-193a-3pDownregulateBind 3′UTRCongenital heart disease[55]
miR-29b/
29c-3p		DownregulateBind 3′UTRFibroblast[56]
miR-200aDownregulateBind 3′UTRRenal fibrogenesis[57]
miR-148bDownregulateBind 3′UTRSkin wound healing[58]
miR-31DownregulateBind 3′UTR Hairpoor[59]
miR-193bDownregulateBind 3′UTRChondrogenesis[60]
miR-466aDownregulateBind 3′UTRAllogeneic transplantation[61]
circUbe2kUpregulateSponge miR-149-5pHepatic fibrosis[62]
circ_0001293UpregulateSponge miR-8114Epilepsy[63]
circRIP2UpregulateSponge miR-1305Bladder cancer[64]
lncRNA CASC9UpregulateSponge miR-758-3pBladder cancer[65]
LncMIATUpregulateSponge miR-16-5pLiver fibrosis[66]
NA, not available.

3. The Physiological and Pathological Roles of TGF-β2

As TGF-β2 and its receptors are ubiquitously expressed in the body, the physiological and pathological roles of TGF-β2 are diverse. Apart from embryonic development, TGF-β2 is involved in the pathogenesis of diseases of the eye system, cardiovascular system, motor system, and immune system, as well as tumorigenesis (Table 4).

3.1. Eye System

Of the three TGF-βs, TGF-β2 is the predominant isoform in the neural retina and retinal pigment epithelium [104]. TGF-β2-induced EMT of retinal pigment epithelium cells is well-established as a major mechanism responsible for the pathogenesis of proliferative retinal diseases [79]. Nintedanib, a tyrosine kinase inhibitor that has anti-inflammation and anti-fibrosis effects, prevents TGF-β2-driven EMT in retinal pigment epithelium cells and may serve as a potential drug for the treatment of proliferative vitreoretinopathies [80]. Similarly, alpha-Klotho, an anti-ageing protein that diminishes with age, reversed EMT and senescence-like morphological alterations triggered by TGF-β2 in retinal pigment epithelium cells [81]. In addition, TGF-β2 has also been shown to be involved in age-related cataracts by promoting EMT and cell proliferation and inhibiting apoptosis in lens epithelial cells (LECs) [82]. Posterior capsular opacification, also known as fibrotic cataract, is partially caused by pathological EMT of LECs. During the EMT progression of LECs, TGF-β2 promoted autophagic flux in a time-dependent manner, which has been reported to play an important role in fibrotic disorders. Rapamycin-induced autophagic activation enhanced the TGF-β2-induced fibrotic response in LECs, whereas pharmacological inhibition of autophagy blunted TGF-β2-induced EMT of LECs, suggesting that increased autophagy is partially responsible for the pro-EMT effect of TGF-β2 in LECs [83]. Interestingly, TGF-β2 increased the expression of the tumour protein p53-inducible nuclear protein2, the knocking down of which blocked TGF-β2-induced autophagy and EMT, suggesting that tumour protein p53-inducible nuclear protein2 is a downstream regulator of autophagy flux induced by TGF-β2 and represents a novel target for the treatment of posterior capsular opacification [84].

3.2. Cardiovascular System

TGF-β2 plays a more prominent role in heart development. For example, Bartram et al. examined the heart of Tgfb2−/− mouse embryos from 11.5 to 18.5 days and detected obvious abnormalities in the outflow tract and atrioventricular channel. These phenotypes reflect the defects in looping, myocardialisation, differentiation of the endocardial cushions, and apoptosis [39]. Azhar et al. also found that the differentiation of endocardial cushions is mainly regulated by TGF-β2. They cultured atrioventricular canal explants from Tgfb1−/−, Tgfb2−/−, and Tgfb3−/− mice on collagen gels and found that TGF-β2 is the only ligand whose absence affects the EMT of the cardiac cushions [105]. The important role of TGF-β2 in vascular development was also highlighted. Researchers used double mutant mice with mutants of fibrillin 1 and TGF-β1, -β2, or -β3 and found that the deletion of TGF-β2, but not TGF-β1 or TGF-β3, resulted in 80% of the offspring dying. Mouse death was associated with hyperplasia of the aortic valve leaflets, aortic regurgitation, and enlargement of the aortic root, etc. [106].
In addition to its role in cardiovascular development, TGF-β2 has also been implicated in the pathological remodelling of the cardiovascular system. In heart diseases, TGF-β2 may be involved in promoting myocardial fibrosis. For example, TGF-β2 acted as a target gene of miR-29b-3p and miR-29c-3p in mouse cardiac fibroblasts, inhibiting the expression of genes associated with fibrosis such as COL1A1, COL3A1, and α-SMA [56]. Lysyl oxidation-like 2 (Loxl2), which is upregulated in the cardiac interstitium and is associated with collagen cross-linking and cardiac dysfunction, promotes the production of TGF-β2 in cardiac fibroblasts via the PI3K/AKT pathway. TGF-β2 is responsible for the transformation of fibroblasts into myofibroblasts induced by Loxl2 [85]. In vascular diseases, aortic aneurysm is a life-threatening feature of fibulin-4 mutated mice that could be reversed with the administration of a TGF-β-neutralising antibody. Further evidence suggests that TGF-β1 upregulation is marginal, whereas TGF-β2 upregulation is more obvious in aortic smooth muscle cells and the plasma of fibulin-4-deficient mice. More importantly, TGF-β2 levels were reduced after treatment with losartan, which is a known anti-aneurysm drug. These results suggest a potential role of TGF-β2 in the pathogenesis of aortic aneurysms [86]. In human carotid plaques, TGF-β2, but not TGF-β1 or TGF-β3, was the most abundant isoform. TGF-β2 expression in asymptomatic plaques was inversely correlated with matrix degradation and inflammation. The risk of cardiovascular events was lower in patients with plaques with high levels of TGF-β2. In vitro, TGF-β2 pretreatment reduced MMPs and monocyte chemoattractant protein-1, which may partially contribute to its protective role in the stabilisation of plaques [87]. Taken together, the above studies suggest that TGF-β2, rather than TGF-β1 or TGF-β3, may be the major player in the cardiovascular system.

3.3. Motor System

TGF-β2 is associated with the development or diseases of the motor system, which includes cartilage, tendon, bone, and skeletal muscle. In the articular cartilage isolated from neonatal mice, TGF-β2 was found to increase cell–cell communication between chondrocytes [88]. In chondrogenic ATDC5 cells of mice, miR-193b was upregulated and inhibited early chondrogenesis. The researchers further identified Tgfb2 and Tgfbr3 as the major target genes of miR-193b in the chondrogenesis of ATDC5 cells. The anti-chondrogenic effect of the miR-193b mimic was reversed with TGF-β2 treatment in a dose-dependent manner, indicating a crucial role of TGF-β2 in early chondrogenesis [60]. In human chondrocytes, TGF-β2 is involved in preserving the chondrocyte phenotype under hypoxic conditions in vitro [89]. Interestingly, in cultured human osteoarthritic cartilage, TGF-β2 was also found to suppress the expression of MMP and differentiation-related genes, thereby suppressing collagen resorption and chondrocyte differentiation [90]. These studies suggest a positive role of TGF-β2 in early chondrogenesis and maintenance of the chondrocyte phenotype. However, in contrast to its effects on chondrocytes and cartilage, TGF-β2 negatively affects skeletal muscle cells and bone formation. For example, in chicken skeletal muscle satellite cells, Tgfb2, which was identified as a target gene of miR-200a-3p, suppressed differentiation and proliferation and accelerated apoptosis of skeletal muscle satellite cells [91]. The osteogenic differentiation of human dental follicle stem cells was suppressed under inflammatory conditions with an obvious upregulation of TGF-β2. The inhibition of TGF-β2 enabled dental follicle stem cells to undergo osteogenic differentiation following lipopolysaccharide stimulation [92]. Tendons are important parts of the musculoskeletal system that are responsible for transferring forces from muscle to bone. miR-378a, by targeting Tgfb2, inhibits collagen and extracellular matrix production, thereby exerting an inhibitory effect on tendon repair both in vitro and in vivo. These results suggest that TGF-β2 is beneficial for tendon repair [93]. Another study also confirmed that treatment with TGF-β2 resulted in a significant upregulation of the expression of collagens, extracellular matrix molecules, and growth factors. This suggests that TGF-β2 is involved in promoting tendon healing by increasing the production of paracrine factors and extracellular matrix molecules [94]. Taken together, these studies suggest that TGF-β2 plays a positive regulatory role in chondrocyte activity and tendon repair and a negative regulatory role in skeletal muscle cell activity and bone formation.

3.4. Immune System

TGF-β is involved in maintaining the homeostasis of the immune system by regulating the activation of immune cells and the secretion of cytokines. Increasing evidence suggests that TGF-β1 plays an important role in the maintenance of immune homeostasis; however, the immunological role of TGF-β2 is not yet fully understood. Molecular evolutionary analyses revealed that lamprey contain two members of TGF-β, i.e., TGF-β2 and TGF-β3, but not TGF-β1, representing ancestors in vertebrates. Then, transcriptional expression patterns further showed that lamprey TGF-β2 is upregulated more rapidly and significantly than TGF-β3 during lipopolysaccharide stimulation. These results suggest that lamprey TGF-β2 may play a more important role in the innate immune response in lamprey [95]. In rodents, TGF-β2, but not TGF-β1, is expressed in neuron-glial antigen 2 glia, which are necessary for maintaining immune homeostasis in the brain. TGF-β2 significantly upregulated two microglial checkpoint genes, i.e., CX3C chemokine receptor 1 (CX3CR1) and Tmem119, and reduced pro-inflammatory mediators both in vitro and in vivo. That study demonstrated that glial-derived TGF-β2 is an important modulator of the CX3CR1-regulated innate immune response in the brain [96]. TGF-β2 can also be secreted by neural precursor cells and direct the transcriptional reprogramming of dendritic cells. Intrathecal administration of TGF-β2 resulted in the amelioration of autoimmune encephalitis, while transplantation of Tgfb2−/− neural precursor cells into mice with experimental autoimmune encephalomyelitis had no effect on immune response cell accumulation [97]. In addition, the presence of TGF-β2 in breast milk is thought to be associated with the maturation of the immune system after birth. Dietary supplementation with TGF-β2 at 35 μg/kg/day can increase IgG1 and IgG2a production and decrease the ratio of Th1/Th2, indicating that TGF-β2 is involved in promoting the maturation of immune development [98]. Breast milk TGF-β2 levels were also negatively correlated with plasma viral load levels [99]. These results suggested that TGF-β2 plays an important role in the regulation of immune cell responses and the maintenance of immune system homeostasis.

3.5. Tumorigenesis

TGF-β2 has been implicated in the development of a variety of cancers, including lung cancer, gastrointestinal stromal cancer, pancreatic cancer, breast cancer, glioma, melanoma, and so on [107,108,109]. Acidosis is a common tumour microenvironment that enables malignant cell proliferation and metastasis [110]. Cancer cells adapted to acidosis could accumulate lipid droplets in the cytosol, which support cancer cell survival and invasiveness. The inhibition of TGF-β2 with antisense oligonucleotide and TβR1 inhibitor prevented lipid droplet formation and significantly reduced cancer cell invasion. These effects were reversed with the replenishment of recombinant TGF-β2. The researchers concluded that TGF-β2 is a key driver of the acidosis-induced lipid metabolism rewiring that is important for cancer cell progression [100]. Culturing mesothelioma cells in an acidic medium increases TGF-β2 secretion, which in turn leads to lipid droplet accumulation in dendritic cells, altering metabolic reprogramming, migratory capacity, the T cell response, and efficacy of anticancer vaccination, which was reversed with SB431542 (TGF-β receptor inhibitor) [101]. The metastasis of lung cancer cells under acidification is associated with miR-7-5p, which is decreased in transgenic mouse models with lung cancer. It can target the 3′UTR of Tgfb2 mRNA. Human lung tumour samples also show reduced expression of miR-7-5p and increased levels of TGF-β2. The researchers identified that acidic pH-enhanced lung cancer metastasis was regulated by the miR-7/TGF-β2 axis [53]. The metalloenzyme tartrate-resistant acid phosphatase (TRAP/ACP5) has recently gained prominence due to its association with clinically relevant cancer parameters. Interestingly, neutralising antibody-mediated TGF-β2 blockade could limit TRAP-dependent proliferation and migration in breast cancer cells [102].
In addition to the tumour-promoting effects, the anti-tumour activities of TGF-β2 have also been reported. For example, miR-193a promotes the proliferation and metastasis of pancreatic cancer cells by inhibiting the TGF-β2/TβR3 pathway. In contrast, the restoration of TGF-β2/TβR3 signalling or knockdown of miR-193a suppressed the repopulation and metastasis of pancreatic cancer cells [103]. GPC3 was found to be elevated in the serum of hepatocellular carcinoma patients, which plays a crucial role in inducing cell proliferation. GPC3 knockdown-mediated cell cycle inhibition could be recapitulated with the addition of human recombinant TGF-β2, suggesting the possible involvement of TGF-β2 in the growth inhibition of hepatocellular carcinoma cells [67]. From these studies, we can conclude that TGF-β2 indeed plays a crucial role in tumour cell proliferation, metastasis, and invasion; however, in vivo practice requires careful evaluation based on different cell types and pathological environments.

4. Conclusions and Remarks

In this review, we summarised the expression, protein processing and secretion, expressional regulation, signalling pathways, and biological roles of TGF-β2 in physiology and pathology. Over the past years, TGF-β2 has literally been considered an analogue of TGF-β1. However, recent studies have gained more insights into the expression, activation, and biological functions of TGF-β2 that are significantly different from TGF-β1. For example, Compared with TGF-β1, the expression of TGF-β2 is more prone to be altered with greater magnitude when exposed to exogenous stimuli. TGF-β2 has high binding affinity to TβR3 and TβR2-B, while TGF-β1 is more inclined to interact with TβR2. The tissue distribution and cell typic expression of TGF-β1and TGF-β2, as well as corresponsive receptors, are also different, which may determine the phenotypic discrepancy between Tgfb1−/− and Tgfb2−/− mice. However, much remains to be understood about the precise mechanism of its role in specific diseases. For example, although Tgfb2−/− mice show remarkable defects in heart and vessel development, the role of TGF-β2 in adulthood cardiovascular diseases is less investigated. Basic studies about the role of TGF-β2 in the urogenital system, palate, and inner ear are also sparse. Studies based on tissue-specific Tgfb2−/− animals are required for a better understanding of the functions of TGF-β2 under physiological and pathological conditions.

Author Contributions

Conceptualisation, J.L.; original draft preparation, M.-Y.W. and L.-Y.W.; writing—review and editing, M.-Y.W., G.W., W.-J.L., L.-Y.W., C.-L.Z. and J.L.; visualisation, M.-Y.W., and W.-J.L.; supervision, L.-Y.W., G.W., C.-L.Z. and J.L.; funding acquisition, G.W., W.-J.L., C.-L.Z. and J.L. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by the Natural Science Foundation of China (82370259, 81970250, 32271151, 82000056), the Natural Science Foundation of Guangdong Province of China (2022A1515012310, 2020A1515010259), and the Basic Research Foundation of Shenzhen Grants (JCYJ20190808121819024, JCYJ20210324094006018).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

Figure 1 was created with VOSviewer software https://www.vosviewer.com/ (accessed on 29 November 2023). Figure 2 was created with SnapGne software https://www.snapgene.com/ (accessed on 20 October 2023). Figure 3 and Figure 4 were created using BioRender.com (accessed on 25 October 2023).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Morikawa, M.; Derynck, R.; Miyazono, K. TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology. Cold Spring Harb. Perspect. Biol. 2016, 8, a021873. [Google Scholar] [CrossRef] [PubMed]
  2. Derynck, R.; Jarrett, J.A.; Chen, E.Y.; Eaton, D.H.; Bell, J.R.; Assoian, R.K.; Roberts, A.B.; Sporn, M.B.; Goeddel, D.V. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 1985, 316, 701–705. [Google Scholar] [CrossRef] [PubMed]
  3. Moses, H.L.; Roberts, A.B.; Derynck, R. The Discovery and Early Days of TGF-β: A Historical Perspective. Cold Spring Harb. Perspect. Biol. 2016, 8, a021865. [Google Scholar] [CrossRef] [PubMed]
  4. Derynck, R.; Budi, E.H. Specificity, versatility, and control of TGF-β family signaling. Sci. Signal. 2019, 12, eaav5183. [Google Scholar] [CrossRef] [PubMed]
  5. Baardsnes, J.; Hinck, C.S.; Hinck, A.P.; O’Connor-McCourt, M.D. TbetaR-II discriminates the high- and low-affinity TGF-beta isoforms via two hydrogen-bonded ion pairs. Biochemistry 2009, 48, 2146–2155. [Google Scholar] [CrossRef]
  6. Shull, M.M.; Ormsby, I.; Kier, A.B.; Pawlowski, S.; Diebold, R.J.; Yin, M.; Allen, R.; Sidman, C.; Proetzel, G.; Calvin, D.; et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992, 359, 693–699. [Google Scholar] [CrossRef] [PubMed]
  7. Kaartinen, V.; Voncken, J.W.; Shuler, C.; Warburton, D.; Bu, D.; Heisterkamp, N.; Groffen, J. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat. Genet. 1995, 11, 415–421. [Google Scholar] [CrossRef]
  8. Sanford, L.P.; Ormsby, I.; Gittenberger-de Groot, A.C.; Sariola, H.; Friedman, R.; Boivin, G.P.; Cardell, E.L.; Doetschman, T. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 1997, 124, 2659–2670. [Google Scholar] [CrossRef]
  9. Foitzik, K.; Paus, R.; Doetschman, T.; Dotto, G.P. The TGF-beta2 isoform is both a required and sufficient inducer of murine hair follicle morphogenesis. Dev. Biol. 1999, 212, 278–289. [Google Scholar] [CrossRef]
  10. Webb, N.R.; Madisen, L.; Rose, T.M.; Purchio, A.F. Structural and sequence analysis of TGF-beta 2 cDNA clones predicts two different precursor proteins produced by alternative mRNA splicing. DNA 1988, 7, 493–497. [Google Scholar] [CrossRef]
  11. Robertson, I.B.; Rifkin, D.B. Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins. Cold Spring Harb. Perspect. Biol. 2016, 8, a021907. [Google Scholar] [CrossRef]
  12. Stockis, J.; Colau, D.; Coulie, P.G.; Lucas, S. Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur. J. Immunol. 2009, 39, 3315–3322. [Google Scholar] [CrossRef]
  13. Rifkin, D.B. Latent transforming growth factor-beta (TGF-beta) binding proteins: Orchestrators of TGF-beta availability. J. Biol. Chem. 2005, 280, 7409–7412. [Google Scholar] [CrossRef]
  14. Tran, D.Q.; Andersson, J.; Wang, R.; Ramsey, H.; Unutmaz, D.; Shevach, E.M. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc. Natl. Acad. Sci. USA 2009, 106, 13445–13450. [Google Scholar] [CrossRef]
  15. Annes, J.P.; Munger, J.S.; Rifkin, D.B. Making sense of latent TGFbeta activation. J. Cell Sci. 2003, 116, 217–224. [Google Scholar] [CrossRef]
  16. Saharinen, J.; Keski-Oja, J. Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta. Mol. Biol. Cell 2000, 11, 2691–2704. [Google Scholar] [CrossRef]
  17. Tzavlaki, K.; Moustakas, A. TGF-β Signaling. Biomolecules 2020, 10, 487. [Google Scholar] [CrossRef]
  18. Aluwihare, P.; Mu, Z.; Zhao, Z.; Yu, D.; Weinreb, P.H.; Horan, G.S.; Violette, S.M.; Munger, J.S. Mice that lack activity of alphavbeta6- and alphavbeta8-integrins reproduce the abnormalities of Tgfb1- and Tgfb3-null mice. J. Cell Sci. 2009, 122, 227–232. [Google Scholar] [CrossRef]
  19. Noma, T.; Glick, A.B.; Geiser, A.G.; O’Reilly, M.A.; Miller, J.; Roberts, A.B.; Sporn, M.B. Molecular cloning and structure of the human transforming growth factor-beta 2 gene promoter. Growth Factors 1991, 4, 247–255. [Google Scholar] [CrossRef]
  20. Jenkins, G. The role of proteases in transforming growth factor-beta activation. Int. J. Biochem. Cell Biol. 2008, 40, 1068–1078. [Google Scholar] [CrossRef]
  21. Sato, Y.; Rifkin, D.B. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: Activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J. Cell Biol. 1989, 109, 309–315. [Google Scholar] [CrossRef]
  22. Akita, K.; Okuno, M.; Enya, M.; Imai, S.; Moriwaki, H.; Kawada, N.; Suzuki, Y.; Kojima, S. Impaired liver regeneration in mice by lipopolysaccharide via TNF-alpha/kallikrein-mediated activation of latent TGF-beta. Gastroenterology 2002, 123, 352–364. [Google Scholar] [CrossRef]
  23. Yu, Q.; Stamenkovic, I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes. Dev. 2000, 14, 163–176. [Google Scholar] [CrossRef]
  24. Dallas, S.L.; Zhao, S.; Cramer, S.D.; Chen, Z.; Peehl, D.M.; Bonewald, L.F. Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. J. Cell Physiol. 2005, 202, 361–370. [Google Scholar] [CrossRef]
  25. Adams, J.C. Thrombospondins: Multifunctional regulators of cell interactions. Annu. Rev. Cell Dev. Biol. 2001, 17, 25–51. [Google Scholar] [CrossRef]
  26. Mir, F.A.; Contreras-Ruiz, L.; Masli, S. Thrombospondin-1-dependent immune regulation by transforming growth factor-β2-exposed antigen-presenting cells. Immunology 2015, 146, 547–556. [Google Scholar] [CrossRef]
  27. Seliger, C.; Leukel, P.; Moeckel, S.; Jachnik, B.; Lottaz, C.; Kreutz, M.; Brawanski, A.; Proescholdt, M.; Bogdahn, U.; Bosserhoff, A.K.; et al. Lactate-modulated induction of THBS-1 activates transforming growth factor (TGF)-beta2 and migration of glioma cells in vitro. PLoS ONE 2013, 8, e78935. [Google Scholar] [CrossRef]
  28. Jobling, M.F.; Mott, J.D.; Finnegan, M.T.; Jurukovski, V.; Erickson, A.C.; Walian, P.J.; Taylor, S.E.; Ledbetter, S.; Lawrence, C.M.; Rifkin, D.B.; et al. Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive oxygen species. Radiat. Res. 2006, 166, 839–848. [Google Scholar] [CrossRef]
  29. Lyons, R.M.; Keski-Oja, J.; Moses, H.L. Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J. Cell Biol. 1988, 106, 1659–1665. [Google Scholar] [CrossRef]
  30. Brown, P.D.; Wakefield, L.M.; Levinson, A.D.; Sporn, M.B. Physicochemical activation of recombinant latent transforming growth factor-beta’s 1, 2, and 3. Growth Factors 1990, 3, 35–43. [Google Scholar] [CrossRef]
  31. Fong, K.D.; Trindade, M.C.; Wang, Z.; Nacamuli, R.P.; Pham, H.; Fang, T.D.; Song, H.M.; Smith, R.L.; Longaker, M.T.; Chang, J. Microarray analysis of mechanical shear effects on flexor tendon cells. Plast. Reconstr. Surg. 2005, 116, 1393–1404. [Google Scholar] [CrossRef]
  32. Ahamed, J.; Burg, N.; Yoshinaga, K.; Janczak, C.A.; Rifkin, D.B.; Coller, B.S. In vitro and in vivo evidence for shear-induced activation of latent transforming growth factor-beta1. Blood 2008, 112, 3650–3660. [Google Scholar] [CrossRef] [PubMed]
  33. Cheifetz, S.; Hernandez, H.; Laiho, M.; ten Dijke, P.; Iwata, K.K.; Massagué, J. Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms. J. Biol. Chem. 1990, 265, 20533–20538. [Google Scholar] [CrossRef]
  34. De Crescenzo, G.; Hinck, C.S.; Shu, Z.; Zúñiga, J.; Yang, J.; Tang, Y.; Baardsnes, J.; Mendoza, V.; Sun, L.; López-Casillas, F.; et al. Three key residues underlie the differential affinity of the TGFbeta isoforms for the TGFbeta type II receptor. J. Mol. Biol. 2006, 355, 47–62. [Google Scholar] [CrossRef]
  35. Sankar, S.; Mahooti-Brooks, N.; Centrella, M.; McCarthy, T.L.; Madri, J.A. Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor beta 2. J. Biol. Chem. 1995, 270, 13567–13572. [Google Scholar] [CrossRef]
  36. Brown, C.B.; Boyer, A.S.; Runyan, R.B.; Barnett, J.V. Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. Science 1999, 283, 2080–2082. [Google Scholar] [CrossRef]
  37. López-Casillas, F.; Wrana, J.L.; Massagué, J. Betaglycan presents ligand to the TGF beta signaling receptor. Cell 1993, 73, 1435–1444. [Google Scholar] [CrossRef]
  38. Stenvers, K.L.; Tursky, M.L.; Harder, K.W.; Kountouri, N.; Amatayakul-Chantler, S.; Grail, D.; Small, C.; Weinberg, R.A.; Sizeland, A.M.; Zhu, H.J. Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos. Mol. Cell Biol. 2003, 23, 4371–4385. [Google Scholar] [CrossRef]
  39. Bartram, U.; Molin, D.G.; Wisse, L.J.; Mohamad, A.; Sanford, L.P.; Doetschman, T.; Speer, C.P.; Poelmann, R.E.; Gittenberger-de Groot, A.C. Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-beta(2)-knockout mice. Circulation 2001, 103, 2745–2752. [Google Scholar] [CrossRef]
  40. López-Casillas, F.; Payne, H.M.; Andres, J.L.; Massagué, J. Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: Mapping of ligand binding and GAG attachment sites. J. Cell Biol. 1994, 124, 557–568. [Google Scholar] [CrossRef]
  41. Rotzer, D.; Roth, M.; Lutz, M.; Lindemann, D.; Sebald, W.; Knaus, P. Type III TGF-beta receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-beta type II receptor. Embo J. 2001, 20, 480–490. [Google Scholar] [CrossRef]
  42. Chida, T.; Ito, M.; Nakashima, K.; Kanegae, Y.; Aoshima, T.; Takabayashi, S.; Kawata, K.; Nakagawa, Y.; Yamamoto, M.; Shimano, H.; et al. Critical role of CREBH-mediated induction of transforming growth factor β2 by hepatitis C virus infection in fibrogenic responses in hepatic stellate cells. Hepatology 2017, 66, 1430–1443. [Google Scholar] [CrossRef] [PubMed]
  43. Jung, Y.S.; Kim, Y.H.; Radhakrishnan, K.; Kim, J.; Lee, I.K.; Cho, S.J.; Kim, D.K.; Dooley, S.; Lee, C.H.; Choi, H.S. Orphan nuclear receptor ERRγ regulates hepatic TGF-β2 expression and fibrogenic response in CCl(4)-induced acute liver injury. Arch. Toxicol. 2021, 95, 3071–3084. [Google Scholar] [CrossRef]
  44. Liu, S.; Jin, K.; Hui, Y.; Fu, J.; Jie, C.; Feng, S.; Reisman, D.; Wang, Q.; Fan, D.; Sukumar, S.; et al. HOXB7 promotes malignant progression by activating the TGFβ signaling pathway. Cancer Res. 2015, 75, 709–719. [Google Scholar] [CrossRef]
  45. Shah, C.A.; Wang, H.; Bei, L.; Platanias, L.C.; Eklund, E.A. HoxA10 regulates transcription of the gene encoding transforming growth factor beta2 (TGFbeta2) in myeloid cells. J. Biol. Chem. 2011, 286, 3161–3176. [Google Scholar] [CrossRef]
  46. Shields, M.A.; Ebine, K.; Sahai, V.; Kumar, K.; Siddiqui, K.; Hwang, R.F.; Grippo, P.J.; Munshi, H.G. Snail cooperates with KrasG12D to promote pancreatic fibrosis. Mol. Cancer Res. 2013, 11, 1078–1087. [Google Scholar] [CrossRef]
  47. Hong, L.; Li, F.; Tang, C.; Li, L.; Sun, L.; Li, X.; Zhu, L. Semaphorin 7A promotes endothelial to mesenchymal transition through ATF3 mediated TGF-β2/Smad signaling. Cell Death Dis. 2020, 11, 695. [Google Scholar] [CrossRef]
  48. Namachivayam, K.; MohanKumar, K.; Arbach, D.; Jagadeeswaran, R.; Jain, S.K.; Natarajan, V.; Mehta, D.; Jankov, R.P.; Maheshwari, A. All-Trans Retinoic Acid Induces TGF-β2 in Intestinal Epithelial Cells via RhoA- and p38α MAPK-Mediated Activation of the Transcription Factor ATF2. PLoS ONE 2015, 10, e0134003. [Google Scholar] [CrossRef]
  49. Serizawa, M.; Murakami, H.; Watanabe, M.; Takahashi, T.; Yamamoto, N.; Koh, Y. Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells. Cancer Sci. 2014, 105, 683–689. [Google Scholar] [CrossRef]
  50. Takahashi, H.; Alves, C.R.R.; Stanford, K.I.; Middelbeek, R.J.W.; Nigro, P.; Ryan, R.E.; Xue, R.; Sakaguchi, M.; Lynes, M.D.; So, K.; et al. TGF-β2 is an exercise-induced adipokine that regulates glucose and fatty acid metabolism. Nat. Metab. 2019, 1, 291–303. [Google Scholar] [CrossRef]
  51. Feng, C.; Zuo, Z. Regulatory factor X1-induced down-regulation of transforming growth factor β2 transcription in human neuroblastoma cells. J. Biol. Chem. 2012, 287, 22730–22739. [Google Scholar] [CrossRef]
  52. Bartel, D.P. Metazoan MicroRNAs. Cell 2018, 173, 20–51. [Google Scholar] [CrossRef] [PubMed]
  53. Su, T.; Huang, S.; Zhang, Y.; Guo, Y.; Zhang, S.; Guan, J.; Meng, M.; Liu, L.; Wang, C.; Yu, D.; et al. miR-7/TGF-β2 axis sustains acidic tumor microenvironment-induced lung cancer metastasis. Acta Pharm. Sin. B 2022, 12, 821–837. [Google Scholar] [CrossRef] [PubMed]
  54. Zhang, W.; Li, Y. miR-148a downregulates the expression of transforming growth factor-β2 and SMAD2 in gastric cancer. Int. J. Oncol. 2016, 48, 1877–1885. [Google Scholar] [CrossRef]
  55. Zhong, L.; Yang, H.; Zhu, B.; Zhao, X.; Xie, M.; Cao, M.; Liu, C.; Zhao, D.; Lyu, Y.; Shang, W.; et al. The TBX1/miR-193a-3p/TGF-β2 Axis Mediates CHD by Promoting Ferroptosis. Oxid. Med. Cell Longev. 2022, 2022, 5130546. [Google Scholar] [CrossRef] [PubMed]
  56. Liang, J.N.; Zou, X.; Fang, X.H.; Xu, J.D.; Xiao, Z.; Zhu, J.N.; Li, H.; Yang, J.; Zeng, N.; Yuan, S.J.; et al. The Smad3-miR-29b/miR-29c axis mediates the protective effect of macrophage migration inhibitory factor against cardiac fibrosis. Biochim. Biophys. Acta Mol. Basis Dis. 2019, 1865, 2441–2450. [Google Scholar] [CrossRef] [PubMed]
  57. Wang, B.; Koh, P.; Winbanks, C.; Coughlan, M.T.; McClelland, A.; Watson, A.; Jandeleit-Dahm, K.; Burns, W.C.; Thomas, M.C.; Cooper, M.E.; et al. miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression. Diabetes 2011, 60, 280–287. [Google Scholar] [CrossRef]
  58. Miscianinov, V.; Martello, A.; Rose, L.; Parish, E.; Cathcart, B.; Mitić, T.; Gray, G.A.; Meloni, M.; Al Haj Zen, A.; Caporali, A. MicroRNA-148b Targets the TGF-β Pathway to Regulate Angiogenesis and Endothelial-to-Mesenchymal Transition during Skin Wound Healing. Mol. Ther. 2018, 26, 1996–2007. [Google Scholar] [CrossRef]
  59. Kim, B.K.; Yoon, S.K. Hairless Up-Regulates Tgf-β2 Expression via Down-Regulation of miR-31 in the Skin of “Hairpoor” (HrHp) Mice. J. Cell Physiol. 2015, 230, 2075–2085. [Google Scholar] [CrossRef]
  60. Hou, C.; Yang, Z.; Kang, Y.; Zhang, Z.; Fu, M.; He, A.; Zhang, Z.; Liao, W. MiR-193b regulates early chondrogenesis by inhibiting the TGF-beta2 signaling pathway. FEBS Lett. 2015, 589, 1040–1047. [Google Scholar] [CrossRef]
  61. Becker, W.; Nagarkatti, M.; Nagarkatti, P.S. miR-466a Targeting of TGF-β2 Contributes to FoxP3(+) Regulatory T Cell Differentiation in a Murine Model of Allogeneic Transplantation. Front. Immunol. 2018, 9, 688. [Google Scholar] [CrossRef]
  62. Zhu, S.; Chen, X.; Wang, J.N.; Xu, J.J.; Wang, A.; Li, J.J.; Wu, S.; Wu, Y.Y.; Li, X.F.; Huang, C.; et al. Circular RNA circUbe2k promotes hepatic fibrosis via sponging miR-149-5p/TGF-β2 axis. Faseb J. 2021, 35, e21622. [Google Scholar] [CrossRef]
  63. Hu, Y.; Meng, B.; Yin, S.; Yang, M.; Li, Y.; Liu, N.; Li, S.; Liu, Y.; Sun, D.; Wang, S.; et al. Scorpion venom peptide HsTx2 suppressed PTZ-induced seizures in mice via the circ_0001293/miR-8114/TGF-β2 axis. J. Neuroinflamm. 2022, 19, 284. [Google Scholar] [CrossRef]
  64. Su, Y.; Feng, W.; Shi, J.; Chen, L.; Huang, J.; Lin, T. circRIP2 accelerates bladder cancer progression via miR-1305/Tgf-β2/smad3 pathway. Mol. Cancer 2020, 19, 23. [Google Scholar] [CrossRef] [PubMed]
  65. Zhang, Z.; Chen, F.; Zhan, H.; Chen, L.; Deng, Q.; Xiong, T.; Li, Y.; Ye, J. lncRNA CASC9 sponges miR-758-3p to promote proliferation and EMT in bladder cancer by upregulating TGF-β2. Oncol. Rep. 2021, 45, 265–277. [Google Scholar] [CrossRef] [PubMed]
  66. Ding, X.; Zhu, X.L.; Xu, D.H.; Li, S.; Yang, Q.; Feng, X.; Wei, Y.G.; Li, H.; Yang, L.; Zhang, Y.J.; et al. NPM promotes hepatotoxin-induced fibrosis by inhibiting ROS-induced apoptosis of hepatic stellate cells and upregulating lncMIAT-induced TGF-β2. Cell Death Dis. 2023, 14, 575. [Google Scholar] [CrossRef]
  67. Sun, C.K.; Chua, M.S.; He, J.; So, S.K. Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2. Neoplasia 2011, 13, 735–747. [Google Scholar] [CrossRef] [PubMed]
  68. Talior-Volodarsky, I.; Arora, P.D.; Wang, Y.; Zeltz, C.; Connelly, K.A.; Gullberg, D.; McCulloch, C.A. Glycated Collagen Induces α11 Integrin Expression Through TGF-β2 and Smad3. J. Cell Physiol. 2015, 230, 327–336. [Google Scholar] [CrossRef]
  69. Norata, G.D.; Callegari, E.; Marchesi, M.; Chiesa, G.; Eriksson, P.; Catapano, A.L. High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. Circulation 2005, 111, 2805–2811. [Google Scholar] [CrossRef]
  70. Wen, F.Q.; Kohyama, T.; Liu, X.; Zhu, Y.K.; Wang, H.; Kim, H.J.; Kobayashi, T.; Abe, S.; Spurzem, J.R.; Rennard, S.I. Interleukin-4- and interleukin-13-enhanced transforming growth factor-beta2 production in cultured human bronchial epithelial cells is attenuated by interferon-gamma. Am. J. Respir. Cell Mol. Biol. 2002, 26, 484–490. [Google Scholar] [CrossRef]
  71. Nagineni, C.N.; Cherukuri, K.S.; Kutty, V.; Detrick, B.; Hooks, J.J. Interferon-gamma differentially regulates TGF-beta1 and TGF-beta2 expression in human retinal pigment epithelial cells through JAK-STAT pathway. J. Cell Physiol. 2007, 210, 192–200. [Google Scholar] [CrossRef]
  72. Felisaz, N.; Boumediene, K.; Ghayor, C.; Herrouin, J.F.; Bogdanowicz, P.; Galerra, P.; Pujol, J.P. Stimulating effect of diacerein on TGF-beta1 and beta2 expression in articular chondrocytes cultured with and without interleukin-1. Osteoarthr. Cartil. 1999, 7, 255–264. [Google Scholar] [CrossRef]
  73. Montorfano, I.; Becerra, A.; Cerro, R.; Echeverría, C.; Sáez, E.; Morales, M.G.; Fernández, R.; Cabello-Verrugio, C.; Simon, F. Oxidative stress mediates the conversion of endothelial cells into myofibroblasts via a TGF-β1 and TGF-β2-dependent pathway. Lab. Investig. 2014, 94, 1068–1082. [Google Scholar] [CrossRef]
  74. Akman, H.O.; Zhang, H.; Siddiqui, M.A.; Solomon, W.; Smith, E.L.; Batuman, O.A. Response to hypoxia involves transforming growth factor-beta2 and Smad proteins in human endothelial cells. Blood 2001, 98, 3324–3331. [Google Scholar] [CrossRef]
  75. Baumann, F.; Leukel, P.; Doerfelt, A.; Beier, C.P.; Dettmer, K.; Oefner, P.J.; Kastenberger, M.; Kreutz, M.; Nickl-Jockschat, T.; Bogdahn, U.; et al. Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2. Neuro Oncol. 2009, 11, 368–380. [Google Scholar] [CrossRef]
  76. Kawakita, T.; Espana, E.M.; Higa, K.; Kato, N.; Li, W.; Tseng, S.C. Activation of Smad-mediated TGF-β signaling triggers epithelial-mesenchymal transitions in murine cloned corneal progenitor cells. J. Cell Physiol. 2013, 228, 225–234. [Google Scholar] [CrossRef]
  77. Bascom, C.C.; Wolfshohl, J.R.; Coffey, R.J., Jr.; Madisen, L.; Webb, N.R.; Purchio, A.R.; Derynck, R.; Moses, H.L. Complex regulation of transforming growth factor beta 1, beta 2, and beta 3 mRNA expression in mouse fibroblasts and keratinocytes by transforming growth factors beta 1 and beta 2. Mol. Cell Biol. 1989, 9, 5508–5515. [Google Scholar] [CrossRef] [PubMed]
  78. Namachivayam, K.; Blanco, C.L.; MohanKumar, K.; Jagadeeswaran, R.; Vasquez, M.; McGill-Vargas, L.; Garzon, S.A.; Jain, S.K.; Gill, R.K.; Freitag, N.E.; et al. Smad7 inhibits autocrine expression of TGF-β2 in intestinal epithelial cells in baboon necrotizing enterocolitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 304, G167–G180. [Google Scholar] [CrossRef] [PubMed]
  79. Suzuki, S.; Sato, T.; Watanabe, M.; Higashide, M.; Tsugeno, Y.; Umetsu, A.; Furuhashi, M.; Ida, Y.; Hikage, F.; Ohguro, H. Hypoxia Differently Affects TGF-β2-Induced Epithelial Mesenchymal Transitions in the 2D and 3D Culture of the Human Retinal Pigment Epithelium Cells. Int. J. Mol. Sci. 2022, 23, 5473. [Google Scholar] [CrossRef] [PubMed]
  80. Yin, Y.; Liu, S.; Pu, L.; Luo, J.; Liu, H.; Wu, W. Nintedanib prevents TGF-β2-induced epithelial-mesenchymal transition in retinal pigment epithelial cells. Biomed. Pharmacother. 2023, 161, 114543. [Google Scholar] [CrossRef]
  81. Jang, H.Y.; Kim, S.J.; Park, K.S.; Kim, J.H. Klotho prevents transforming growth factor-β2-induced senescent-like morphological changes in the retinal pigment epithelium. Cell Death Dis. 2023, 14, 334. [Google Scholar] [CrossRef] [PubMed]
  82. Yao, L.; Yang, L.; Song, H.; Liu, T.; Yan, H. MicroRNA miR-29c-3p modulates FOS expression to repress EMT and cell proliferation while induces apoptosis in TGF-β2-treated lens epithelial cells regulated by lncRNA KCNQ1OT1. Biomed. Pharmacother. 2020, 129, 110290. [Google Scholar] [CrossRef]
  83. Sun, Y.; Xiong, L.; Wang, X.; Wang, L.; Chen, B.; Huang, J.; Huang, M.; Chen, J.; Wu, J.; Huang, S.; et al. Autophagy inhibition attenuates TGF-β2-induced epithelial-mesenchymal transition in lens epithelial cells. Life Sci. 2021, 265, 118741. [Google Scholar] [CrossRef]
  84. Cui, Y.; Yang, H.; Shi, S.; Ping, X.; Zheng, S.; Tang, X.; Yu, X.; Shentu, X. TP53INP2 Contributes to TGF-β2-Induced Autophagy during the Epithelial-Mesenchymal Transition in Posterior Capsular Opacification Development. Cells 2022, 11, 2385. [Google Scholar] [CrossRef]
  85. Yang, J.; Savvatis, K.; Kang, J.S.; Fan, P.; Zhong, H.; Schwartz, K.; Barry, V.; Mikels-Vigdal, A.; Karpinski, S.; Kornyeyev, D.; et al. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nat. Commun. 2016, 7, 13710. [Google Scholar] [CrossRef]
  86. Ramnath, N.W.; Hawinkels, L.J.; van Heijningen, P.M.; te Riet, L.; Paauwe, M.; Vermeij, M.; Danser, A.H.; Kanaar, R.; ten Dijke, P.; Essers, J. Fibulin-4 deficiency increases TGF-β signalling in aortic smooth muscle cells due to elevated TGF-β2 levels. Sci. Rep. 2015, 5, 16872. [Google Scholar] [CrossRef]
  87. Edsfeldt, A.; Singh, P.; Matthes, F.; Tengryd, C.; Cavalera, M.; Bengtsson, E.; Dunér, P.; Volkov, P.; Karadimou, G.; Gisterå, A.; et al. Transforming growth factor-β2 is associated with atherosclerotic plaque stability and lower risk for cardiovascular events. Cardiovasc. Res. 2023, 119, 2061–2073. [Google Scholar] [CrossRef]
  88. Duan, M.; Liu, Y.; Guo, D.; Kan, S.; Niu, Z.; Pu, X.; Bai, M.; Zhang, D.; Du, W.; Xie, J. TGF-β2 increases cell-cell communication in chondrocytes via p-Smad3 signalling. Biochim. Biophys. Acta Mol. Cell Res. 2022, 1869, 119175. [Google Scholar] [CrossRef] [PubMed]
  89. Das, R.; Timur, U.T.; Edip, S.; Haak, E.; Wruck, C.; Weinans, H.; Jahr, H. TGF-β2 is involved in the preservation of the chondrocyte phenotype under hypoxic conditions. Ann. Anat. Anat. Anz. Off. Organ. Anat. Ges. 2015, 198, 1–10. [Google Scholar] [CrossRef]
  90. Tchetina, E.V.; Antoniou, J.; Tanzer, M.; Zukor, D.J.; Poole, A.R. Transforming growth factor-beta2 suppresses collagen cleavage in cultured human osteoarthritic cartilage, reduces expression of genes associated with chondrocyte hypertrophy and degradation, and increases prostaglandin E(2) production. Am. J. Pathol. 2006, 168, 131–140. [Google Scholar] [CrossRef] [PubMed]
  91. Yin, H.; He, H.; Shen, X.; Tang, S.; Zhao, J.; Cao, X.; Han, S.; Cui, C.; Chen, Y.; Wei, Y.; et al. MicroRNA Profiling Reveals an Abundant miR-200a-3p Promotes Skeletal Muscle Satellite Cell Development by Targeting TGF-β2 and Regulating the TGF-β2/SMAD Signaling Pathway. Int. J. Mol. Sci. 2020, 21, 3274. [Google Scholar] [CrossRef]
  92. Um, S.; Lee, J.H.; Seo, B.M. TGF-β2 downregulates osteogenesis under inflammatory conditions in dental follicle stem cells. Int. J. Oral. Sci. 2018, 10, 29. [Google Scholar] [CrossRef] [PubMed]
  93. Liu, Y.; Feng, L.; Xu, J.; Yang, Z.; Wu, T.; Zhang, J.; Shi, L.; Zhu, D.; Zhang, J.; Li, G. MiR-378a suppresses tenogenic differentiation and tendon repair by targeting at TGF-β2. Stem Cell Res. Ther. 2019, 10, 108. [Google Scholar] [CrossRef]
  94. Koch, D.W.; Schnabel, L.V.; Ellis, I.M.; Bates, R.E.; Berglund, A.K. TGF-β2 enhances expression of equine bone marrow-derived mesenchymal stem cell paracrine factors with known associations to tendon healing. Stem Cell Res. Ther. 2022, 13, 477. [Google Scholar] [CrossRef]
  95. Liu, S.; Guo, J.; Cheng, X.; Li, W.; Lyu, S.; Chen, X.; Li, Q.; Wang, H. Molecular Evolution of Transforming Growth Factor-β (TGF-β) Gene Family and the Functional Characterization of Lamprey TGF-β2. Front. Immunol. 2022, 13, 836226. [Google Scholar] [CrossRef]
  96. Zhang, S.Z.; Wang, Q.Q.; Yang, Q.Q.; Gu, H.Y.; Yin, Y.Q.; Li, Y.D.; Hou, J.C.; Chen, R.; Sun, Q.Q.; Sun, Y.F.; et al. NG2 glia regulate brain innate immunity via TGF-β2/TGFBR2 axis. BMC Med. 2019, 17, 204. [Google Scholar] [CrossRef] [PubMed]
  97. De Feo, D.; Merlini, A.; Brambilla, E.; Ottoboni, L.; Laterza, C.; Menon, R.; Srinivasan, S.; Farina, C.; Garcia Manteiga, J.M.; Butti, E.; et al. Neural precursor cell-secreted TGF-β2 redirects inflammatory monocyte-derived cells in CNS autoimmunity. J. Clin. Investig. 2017, 127, 3937–3953. [Google Scholar] [CrossRef]
  98. Torres-Castro, P.; Grases-Pintó, B.; Abril-Gil, M.; Castell, M.; Rodríguez-Lagunas, M.J.; Pérez-Cano, F.J.; Franch, À. Modulation of the Systemic Immune Response in Suckling Rats by Breast Milk TGF-β2, EGF and FGF21 Supplementation. Nutrients 2020, 12, 1888. [Google Scholar] [CrossRef] [PubMed]
  99. Mabaya, L.; Matarira, H.T.; Tanyanyiwa, D.M.; Musarurwa, C.; Mukwembi, J. Levels of Total Antioxidant Capacity, sCD14, and TGF-β2 in Breast Milk Plasma of HIV-Infected and HIV-Uninfected Lactating Women. Breastfeed. Med. Off. J. Acad. Breastfeed. Med. 2021, 16, 821–826. [Google Scholar] [CrossRef]
  100. Corbet, C.; Bastien, E.; Santiago de Jesus, J.P.; Dierge, E.; Martherus, R.; Vander Linden, C.; Doix, B.; Degavre, C.; Guilbaud, C.; Petit, L.; et al. TGFβ2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. Nat. Commun. 2020, 11, 454. [Google Scholar] [CrossRef]
  101. Trempolec, N.; Degavre, C.; Doix, B.; Brusa, D.; Corbet, C.; Feron, O. Acidosis-Induced TGF-β2 Production Promotes Lipid Droplet Formation in Dendritic Cells and Alters Their Potential to Support Anti-Mesothelioma T Cell Response. Cancers 2020, 12, 1284. [Google Scholar] [CrossRef] [PubMed]
  102. Reithmeier, A.; Panizza, E.; Krumpel, M.; Orre, L.M.; Branca, R.M.M.; Lehtiö, J.; Ek-Rylander, B.; Andersson, G. Tartrate-resistant acid phosphatase (TRAP/ACP5) promotes metastasis-related properties via TGFβ2/TβR and CD44 in MDA-MB-231 breast cancer cells. BMC Cancer 2017, 17, 650. [Google Scholar] [CrossRef] [PubMed]
  103. Fang, C.; Dai, C.Y.; Mei, Z.; Jiang, M.J.; Gu, D.N.; Huang, Q.; Tian, L. microRNA-193a stimulates pancreatic cancer cell repopulation and metastasis through modulating TGF-β2/TGF-βRIII signalings. J. Exp. Clin. Cancer Res. 2018, 37, 25. [Google Scholar] [CrossRef] [PubMed]
  104. Pfeffer, B.A.; Flanders, K.C.; Guérin, C.J.; Danielpour, D.; Anderson, D.H. Transforming growth factor beta 2 is the predominant isoform in the neural retina, retinal pigment epithelium-choroid and vitreous of the monkey eye. Exp. Eye Res. 1994, 59, 323–333. [Google Scholar] [CrossRef] [PubMed]
  105. Azhar, M.; Runyan, R.B.; Gard, C.; Sanford, L.P.; Miller, M.L.; Andringa, A.; Pawlowski, S.; Rajan, S.; Doetschman, T. Ligand-specific function of transforming growth factor beta in epithelial-mesenchymal transition in heart development. Dev. Dyn. 2009, 238, 431–442. [Google Scholar] [CrossRef] [PubMed]
  106. Sachan, N.; Phoon, C.K.L.; Zilberberg, L.; Kugler, M.C.; Ene, T.; Mintz, S.B.; Murtada, S.I.; Weiss, D.; Fishman, G.I.; Humphrey, J.D.; et al. TGFβ-2 haploinsufficiency causes early death in mice with Marfan syndrome. Matrix Biol. J. Int. Soc. Matrix Biol. 2023, 121, 41–55. [Google Scholar] [CrossRef] [PubMed]
  107. Caja, L.; Dituri, F.; Mancarella, S.; Caballero-Diaz, D.; Moustakas, A.; Giannelli, G.; Fabregat, I. TGF-β and the Tissue Microenvironment: Relevance in Fibrosis and Cancer. Int. J. Mol. Sci. 2018, 19, 1294. [Google Scholar] [CrossRef]
  108. Colak, S.; Ten Dijke, P. Targeting TGF-β Signaling in Cancer. Trends Cancer 2017, 3, 56–71. [Google Scholar] [CrossRef]
  109. Peng, D.; Fu, M.; Wang, M.; Wei, Y.; Wei, X. Targeting TGF-β signal transduction for fibrosis and cancer therapy. Mol. Cancer 2022, 21, 104. [Google Scholar] [CrossRef]
  110. Corbet, C.; Feron, O. Tumour acidosis: From the passenger to the driver’s seat. Nat. Rev. Cancer 2017, 17, 577–593. [Google Scholar] [CrossRef]
Cells 12 02739 g001
Figure 1. Statistics of TGF-β2-related publications and network visualisation of keywords. (A) The trend in TGF-β2 publications from the time of discovery to the present day. (B) The result of keyword analysis of TGF-β2-related literature using VOSviewer bibliometrics software, https://www.vosviewer.com/ (accessed on 29 November 2023). The color of dots and lines represent the average year of publication for the corresponding term.
Figure 1. Statistics of TGF-β2-related publications and network visualisation of keywords. (A) The trend in TGF-β2 publications from the time of discovery to the present day. (B) The result of keyword analysis of TGF-β2-related literature using VOSviewer bibliometrics software, https://www.vosviewer.com/ (accessed on 29 November 2023). The color of dots and lines represent the average year of publication for the corresponding term.
Cells 12 02739 g001
Cells 12 02739 g002
Figure 2. The protein structure and sequence alignment of TGF-β2 between species. (A) Conservative analysis of TGF-β2 in Homo sapiens, Gallus gallus, Mus musculus, Xenopus tropicalis, and Danio rerio using SnapGene with a threshold of 90%, highlighted in blue. Sequence conservation was shown by colored blocks on the top. (B) Schematic diagram of the structure of the amino acid sequence of the two precursor proteins of TGF-β2 in Homo sapiens.
Figure 2. The protein structure and sequence alignment of TGF-β2 between species. (A) Conservative analysis of TGF-β2 in Homo sapiens, Gallus gallus, Mus musculus, Xenopus tropicalis, and Danio rerio using SnapGene with a threshold of 90%, highlighted in blue. Sequence conservation was shown by colored blocks on the top. (B) Schematic diagram of the structure of the amino acid sequence of the two precursor proteins of TGF-β2 in Homo sapiens.
Cells 12 02739 g002
Cells 12 02739 g003
Figure 3. A schematic model of the processing and secretion of TGF-β. The sequential biochemical events are shown from the top left to bottom left, indicated with black arrows. In the lumen of the endoplasmic reticulum (ER), the signal peptide of TGF-β is cleaved by signal peptidase to produce a propeptide, which is further cleaved by furin protease. The latent-associated peptide (LAP) and the mature peptide form a dimerised complex called the small latent complex (SLC). The large latent complex (LLC) is then formed by cross-linking SLC with LTBP with disulfide bonds. LLC is transported to the Golgi apparatus and then released into the extracellular matrix (ECM) where LLC is cross-linked to fibrillin and fibronectin. Upon stimulation by activation-related factors, the complex can be depolymerised to release the active TGF-β2 ligand.
Figure 3. A schematic model of the processing and secretion of TGF-β. The sequential biochemical events are shown from the top left to bottom left, indicated with black arrows. In the lumen of the endoplasmic reticulum (ER), the signal peptide of TGF-β is cleaved by signal peptidase to produce a propeptide, which is further cleaved by furin protease. The latent-associated peptide (LAP) and the mature peptide form a dimerised complex called the small latent complex (SLC). The large latent complex (LLC) is then formed by cross-linking SLC with LTBP with disulfide bonds. LLC is transported to the Golgi apparatus and then released into the extracellular matrix (ECM) where LLC is cross-linked to fibrillin and fibronectin. Upon stimulation by activation-related factors, the complex can be depolymerised to release the active TGF-β2 ligand.
Cells 12 02739 g003
Cells 12 02739 g004
Figure 4. The signal transduction of TGF-β2. In cells with TβR3 receptors, active TGF-β2 firstly binds to TβR3 and then recruits TβR2 and TβR1. Finally, TβR3 is dissociated from the above complex and eventually forms the TGF-β2/TβR1/TβR2 complex. Intracellular signalling is mediated by both canonical and non-canonical signalling pathways that regulate the expression of target genes.
Figure 4. The signal transduction of TGF-β2. In cells with TβR3 receptors, active TGF-β2 firstly binds to TβR3 and then recruits TβR2 and TβR1. Finally, TβR3 is dissociated from the above complex and eventually forms the TGF-β2/TβR1/TβR2 complex. Intracellular signalling is mediated by both canonical and non-canonical signalling pathways that regulate the expression of target genes.
Cells 12 02739 g004
Table 1. A comparison of the phenotypes of TGF-β1, -β2, and -β3 knockout mice [6,7,8,9].
Table 1. A comparison of the phenotypes of TGF-β1, -β2, and -β3 knockout mice [6,7,8,9].
OrganTgfb1−/−Tgfb2−/−Tgfb3−/−
HeartGeneralised and extensive infiltration of inflammatory cells involving the pericardium, the myocardium, and the endocardium of the atria and ventriclesCongenital structural defects of the heart, including the arterial outflow tract, aortic and pulmonary orifices, atrioventricular valves, ventricular septum, and myocardiumNA
LungLymphocytic and plasmacytic infiltrationConducting airways collapsedBranching morphogenesis and respiratory epithelial cell differentiation defects
LiverGranulocyte and lymphocyte infiltration, multifocal hepatic necrosis and microgranulomasNANA
PancreasLymphocytic and plasmacytic infiltrationNANA
StomachNeutrophil and eosinophil cell infiltration NANA
Salivary glandLymphocytic and plasmacytic infiltrationNANA
Striated muscleLymphocytic and plasmacytic infiltration NANA
Brain Granulocyte and lymphocyte infiltrationNANA
EyeConjunctivitis, ocular striated muscle inflammation, lacrimal gland inflammationHypercellular infusion in the posterior chamber, hyperplastic retinaNA
SkeletalNALimb laxity, spina bifida occulta, sternum malformations, abnormal curvature of the ribsNA
CraniofacialNARetrognathia, dysmorphic calvariaNA
UrogenitalNAAgenesis renal pelvis, testicular ectopia and hypoplasia, ectopia of the uterine horns, degeneration of kidney tubular epithelium, adrenal ectopiaNA
PalateNACleft palate
(partial penetrance, extensive palate cleft)		Cleft palate
(full penetrance, soft palate cleft not involved)
Inner earNAAbsent spiral limbus and Rosenthal’s canal, undifferentiated inter-dental cells, partially canalised scala vestibuliNA
Hair follicleSlightly advanced hair follicle formationProfound delay in hair follicle morphogenesisNA
Other phenotypesSlight enlargement of lymph nodes, smaller spleen and less distinct white pulpCongenital cyanosisNA
NA, not available.
Table 4. The physiological and pathological effects of TGF-β2 or TGF-β2 inhibition.
Table 4. The physiological and pathological effects of TGF-β2 or TGF-β2 inhibition.
OrgansConsequencesTreatmentsReference
Eye systemInduces EMT
(EMT of retinal pigment epithelial cells is a key mechanism in proliferative retinal diseases)		Human retinal pigment epithelium cells
(20 ng/mL TGF-β2)		[79,80]
Induces senescence and EMT
(Degenerative changes in the retinal pigment epithelium play a critical role in the progression of age-related macular degeneration)		Human retinal pigment epithelial cell and human lens epithelial cells
(10 ng/mL or 12.5 ng/mL TGF-β2)		[81,82]
Promote autophagy and EMT
(Autophagy plays an important role in fibrotic cataracts) 		Rabbit lens epithelial cells and human lens epithelial cells
(5 ng/mL or
10 ng/mL TGF-β2)		[83,84]
Cardiovascular systemPromote cardiac fibrosis
(Loxl2 stimulates cardiac fibrosis by inducing TGF-β2; MiR-29b-3p and miR-29c-3p inhibit cardiac fibrosis by targeting Tgfb2) 		Loxl2-treated TAC hearts and mouse cardiac fibroblasts from Ang-II-infused Mif-KO mice [56,85]
Be associated with aortic aneurysm formationTGF-β2 is elevated at higher levels in the conditioned medium from fibulin-4 deficient mice aortic smooth muscle cells, aortic lysates, and blood[86]
Reduce inflammation and matrix degradation and may be involved in maintaining plaque stabilityRAW 264.7 cells and human THP-1 blood monocytes
(5 ng/mL TGF-β2)		[87]
Motor systemIncrease chondrocyte communication, early chondrogenesis, maintain phenotype, and inhibit differentiation Mouse chondrocytes and human osteoarthritic cartilage
(5/10/25 ng/mL TGF-β2)		[60,88,89,90]
Inhibit skeletal muscle satellite cell differentiation and proliferation and promote apoptosisChicken skeletal muscle satellite cells
(Inhibition of TGF-β2 by miR-200a-3p) 		[91]
Downregulate bone formationHuman dental follicle stem cells
(1 μg/mL TGF-β2 inhibitor)		[92]
Upregulate gene expression of collagens, extracellular matrix molecules, and growth factors associated with tendon healingMouse tendon-derived stem cells and equine bone marrow-derived mesenchymal stem cells
(1 ng/mL TGF-β2)		[93,94]
Immune systemAffect immune cell proliferation and apoptosisMCF-7 cells, RAW 264.7 cells, lamprey supraneural myeloid body cells, and peripheral blood leukocytes
(0.01/0.1/1/10 ng/mL TGF-β2)		[95]
Maintain brain immune homeostasis by regulating the chemokine receptor-modulated immune response in microglia Mouse NG2 glial cells
(5 ng/mL or
10 ng/mL TGF-β2)		[96]
Redirect inflammatory monocyte-derived cells in central nervous system autoimmunityNeural precursor cells from Tgfb2tm1Doe mice (Tgfb2−/−) and bone marrow-derived dendritic cells (0.01/1/10/100 ng/mL TGF-β2)[97]
Promote the maturation of immune developmentG15 pregnant Wistar rats
(TGF-β2 at 35 μg/kg/day)		[98]
Have an impact on antiviral immunityHIV breast feeding women[99]
TumorSustain acidic tumor microenvironment-
induced lung cancer metastasis		Human lung cancer cells
(5 μg/mL of anti-TGF-β2 antibody)		[53]
Inhibit growth of hepatocellular carcinoma cellsHuman hepatocellular carcinoma cells
(1 ng/mL or
5 ng/mL TGF-β2)		[67]
Support acidosis-driven EMT and the metastatic spreading of cancer cellsHuman cervix SiHa, pharynx FaDu, colorectal HCT-116, and HT-29 cancer cell lines
(10 µM TGFβ2-specific antisense oligonucleotide)		[100]
Decrease dendritic cells migratory potential and activation and the anticancer immune responseMouse bone marrow-derived dendritic cells
(5 µM TGF-β receptor inhibitor)		[101]
Mediate the effects of TRAP-dependent proliferation and migration in breast cancer cellsMDA-MB-231 breast cancer cell line
(0.25 μg/mL TGF-β2 neutralising antibody)		[102]
Block pancreatic cancer repopulation and metastasisHuman pancreatic cancer cell lines
(Inhibition of TGF-β2 by miR-193a)		[103]
NA, not available.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Wang, M.-Y.; Liu, W.-J.; Wu, L.-Y.; Wang, G.; Zhang, C.-L.; Liu, J. The Research Progress in Transforming Growth Factor-β2. Cells 2023, 12, 2739. https://doi.org/10.3390/cells12232739

AMA Style

Wang M-Y, Liu W-J, Wu L-Y, Wang G, Zhang C-L, Liu J. The Research Progress in Transforming Growth Factor-β2. Cells. 2023; 12(23):2739. https://doi.org/10.3390/cells12232739

Chicago/Turabian Style

Wang, Meng-Yan, Wen-Juan Liu, Le-Yi Wu, Gang Wang, Cheng-Lin Zhang, and Jie Liu. 2023. "The Research Progress in Transforming Growth Factor-β2" Cells 12, no. 23: 2739. https://doi.org/10.3390/cells12232739

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop